Recent developments in leishmaniasis: Epidemiology, diagnosis, and treatment

被引：45

作者：

Berman J. ^{[1
]}

机构：

[1] Office of Clin./Regulatory Affairs, Natl. Ctr. Complementary/Alt. Med., National Institutes of Health, Bethesda, MD 20892

来源：

Current Infectious Disease Reports | 2005年 / 7卷 / 1期

关键词：

Visceral Leishmaniasis; Leishmaniasis; Cutaneous Leishmaniasis; Liposomal Amphotericin; Paromomycin;

D O I：

10.1007/s11908-005-0021-1

中图分类号：

学科分类号：

摘要：

The outbreaks of cutaneous disease caused by Leishmania tropica in Afghan refugees, visceral disease in Sudanese refugees, and cutaneous disease caused by Leishmania major in American forces in Iraq are examples of the large number of cases of leishmaniasis that can result when naïve human populations intrude into regions where transmission is endemic. Injections of pentavalent antimony for 20 to 30 days have been the standard treatment for all forms of leishmaniasis, but resistance is growing and antimonials have moderate toxicity. Two major advances in the treatment of visceral leishmaniasis have been made in the past few years. Liposomal amphotericin B cures virtually all patients, with little side effects. Miltefosine is the first oral agent that is effective. For cutaneous disease, alternatives to antimony have been effective in certain regions but have not yet been generally evaluated. Copyright © 2005 by Current Science Inc.

引用

页码：33 / 38

页数：5

共 31 条

[1]

Irajhi A.A., Ibrahim E.A., De Vol E.B., Et al., Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major, N. Engl. J. Med., 346, pp. 891-895, (2002)

[2]

Herwaldt B.L., Arana B.A., Navin T.R., The natural history of cutaneous leishmaniasis in Guatemala, J. Infect. Dis., 165, pp. 518-527, (1992)

[3]

Navin T.R., Arana B.A., Arana F.E., Et al., Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala, J. Infect. Dis., 165, pp. 528-534, (1992)

[4]

Velez I., Agudelo S., Hendrickx E., Et al., Inefficacy of allopurinol for Colombian cutaneous leishmaniasis: A randomized, controlled trial, Ann. Intern. Med., 126, pp. 232-236, (1997)

[5]

Desjeux P., Worldwide increasing risk factors for leishmaniasis, Med. Microbiol. Immunol., 190, pp. 77-79, (2001)

[6]

Reithinger R., Mohsen H., Aadil K., Et al., Anthroponotic cutaneous leishmaniasis Kabul, Afghanistan, Emerg. Infect. Dis., 9, pp. 727-729, (2003)

[7]

Update: Cutaneous leishmaniasis in US military personnel - Southwest/Central Asia, 2002-2004, MMWR Morb. Mortal Wkly. Rep., 53, pp. 264-265, (2004)

[8]

Davies C.R., Reithinger R., Campbell-Lendrum D., Et al., The epidemiology and control of leishmaniasis in Andean countries, Cad Saude Publica, 16, pp. 925-950, (2000)

[9]

Ramirez J.R., Adugelo S., Muskus C., Et al., Diagnosis of cutaneous leishmaniasis in Colombia: The sampling site within lesions influences the sensitivity of parasitological diagnosis, J. Clin. Microbiol., 38, pp. 3768-3773, (2000)

[10]

Weigle K.A., Labrada L.A., Lozano C., Et al., PCR-based diagnosis of acute and chronic cutaneous leishmaniasis caused by Leishmania (viannia), J. Clin. Microbiol., 40, pp. 601-606, (2002)

← 1 2 3 4 →